What Penumbra Inc does.

References herein to “we,” “us,” “our,” the “Company,” and “Penumbra,” refer to Penumbra, Inc. and its consolidated subsidiaries unless expressly indicated or the context requires otherwise.

Penumbra, the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety, and simplicity. Our team focuses on developing, manufacturing and marketing novel products for use by specialist physicians and other healthcare providers to drive improved clinical and health outcomes. We believe that the cost-effectiveness of our products is attractive to our customers.

Since our founding in 2004, we have invested heavily in our product development and commercial expansion that has established the foundation of our global organization. We have successfully developed, obtained regulatory clearance or approval for, and introduced products into the thrombectomy market since 2007, access market since 2008, embolization market since 2011, and neurosurgical market since 2014.

Revenue and profit, by fiscal year.

More on PEN.

• Penumbra Inc summary
• Penumbra Inc financial statements
• Penumbra Inc key metrics
• Penumbra Inc health scores and style box
• Penumbra Inc earnings
• Penumbra Inc dividends
• Penumbra Inc valuation
• Penumbra Inc ownership and insiders
• Penumbra Inc peers

Figures from Penumbra Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.